Attached files

file filename
8-K - FORM 8-K - SAVIENT PHARMACEUTICALS INCd729559d8k.htm
EX-99.1 - EX-99.1 - SAVIENT PHARMACEUTICALS INCd729559dex991.htm

Exhibit 99.2

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

    x   

 

In re:

 

SAVIENT PHARMACEUTICALS, INC.,

et al.,

 

Debtors.1

 

 

:

:

:

:

:

:

:

:

x

  

 

Chapter 11

 

Case No. 13-12680 (MFW)

 

Jointly Administered

NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT

FOR THE PERIOD OF APRIL 1, 2014 THROUGH APRIL 30, 2014

PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the above-captioned cases (together, the “Debtors”) filed today the Debtors’ Monthly Operating Report for the Period of April 1, 2014 through April 30, 2014, a copy of which is attached hereto as Exhibit A (the “Monthly Operating Report”).

Dated: Wilmington, Delaware

           May 19, 2014

 

 

COLE, SCHOTZ, MEISEL, FORMAN

  & LEONARD, P.A.

 

/s/ David R. Hurst                                        

David R. Hurst (I.D. No. 3743)

J. Kate Stickles (I.D. No. 2917)

500 Delaware Avenue, Suite 1410

Wilmington, Delaware 19801

Telephone: (302) 652-3131

Facsimile: (302) 652-3117

 

Counsel for Debtors and Debtors-in-Possession

 

 

1  The Debtors and the last four digits of their respective taxpayer identification numbers are as follows: Savient Pharmaceuticals, Inc. (3811); and Savient Pharma Holdings, Inc. (0701). The address of the Debtors’ corporate headquarters is 400 Crossing Boulevard, 4th Floor, Bridgewater, New Jersey 08807.


EXHIBIT A

Monthly Operating Report


UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Savient Pharmaceuticals, Inc., et al   

Case No.13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

MONTHLY OPERATING REPORT

 

REQUIRED DOCUMENTS        Form No.          

Document        

Attached        

 

Explanation        

Attached**        

   Affidavit/Supplement        
Attached**        
         

Schedule of Cash Receipts and Disbursements

   MOR-1   Yes         

Bank Reconciliation (or copies of debtor’s bank reconciliation

   MOR-1a   Yes         

Schedule of Professional Fees Paid

   MOR-1b   Yes         

Copies of bank statements

       No   Yes     

Cash disbursements journals

       No   Yes     

Statement of Operations

   MOR-2   Yes         

Balance Sheet

   MOR-3   Yes         

Status of Postpetition Taxes

   MOR-4   Yes         

Copies of IRS Form 6123 or payment receipt

       No   Yes     

Copies of tax returns filed during reporting period

       No   Yes     

Summary of Unpaid Postpetition Debts

   MOR-4   Yes         

Listing of aged accounts payable

   MOR-4   Yes         

Accounts Receivable Reconciliation and Aging

   MOR-5   Yes         

Debtor Questionnaire

   MOR-5   Yes                 
** Explaination and Affidavit/Supplement are attached as a part of the Company’s General Notes

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

 

 

Signature of Debtor

    

 

Date

  

 

Signature of Joint Debtor

    

 

Date

  

/s/ Mathew C. Bazley

Signature of Authorized Individual*

    

May 19, 2014

Date

  

Mathew C. Bazley

Printed Name of Authorized Individual

    

Chief Liquidation Officer, President and Secretary

Title of Authorized Individual

  


In re: Savient Pharmaceuticals, Inc. et al.   

Case Nos. 13-12680, 13-12681 (MFW)

Reporting Period: 4/1/2014 - 4/30/2014

NOTES TO THE MONTHLY OPERATING REPORT

General Notes

Debtors. Debtor Savient Pharmaceuticals, Inc. is referred to herein as “Savient” or “SPI,” and Debtor Savient Pharma Holdings, Inc. is referred to herein as “SPHI.”

Debtor-in-Possession Financial Statements. The Debtors’ financial statements and supplemental information contained herein are unaudited, preliminary and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects.

Accounting Standards Codification, (“ASC”) 852-10, Reorganizations, which incorporated the guidance in American Institute of Certified Public Accountants Statement of Position 90-7, Financial Reporting by Entities in Reorganization under the Bankruptcy Code, (SOP 90-7), is applicable to companies in chapter 11 and generally does not change the manner in which financial statements are prepared. It does require, however, that the financial statements for periods subsequent to the filing of the chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of business.

The Debtors’ financial statements contained herein have been prepared in accordance with the guidance in ASC 852-10. The unaudited financial statements have been derived from the books and records of the Debtors. This information, however, has not been subject to procedures that would typically be applied to financial information presented in accordance with U.S GAAP, and upon the application of such procedures, the Debtors believe that the financial information could be subject to changes, and these changes could be material. The information furnished in this report includes primarily normal recurring adjustments, but does not include all of the adjustments that would be typically made in accordance with U.S. GAAP.

The results of operations contained herein are not necessarily indicative of results that are expected from any other period or for the full year and may not necessarily reflect the combined results of operations, financial position and cash flows of the Debtors in the future.

Intercompany Transactions. Receivables and payables between the Debtors and/or Non-Debtors have not been eliminated.

Liabilities Subject to Compromise. As a result of the chapter 11 filings, the payment of prepetition indebtedness is subject to compromise or other treatment under a plan of reorganization or liquidation.

The determination of how liabilities ultimately will be settled and treated cannot be made until the United States Bankruptcy Court for the District of Delaware approves a chapter 11 plan of reorganization or liquidation. Accordingly, the ultimate amount of such liabilities is not determinable at this time. Revenues, expenses, realized gains and losses and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the Debtors’ statements of operations.


The Debtors’ balance sheets, in addition, must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from postpetition liabilities. Liabilities that may be affected by a plan of reorganization or liquidation must be reported at the amounts expected to be allowed, even if they may be settled for lesser amounts. In addition, cash provided by reorganization items must be disclosed separately in the Debtors’ statements of cash flows. The amounts currently classified as liabilities subject to compromise are preliminary and may be subject to future adjustments depending on Court actions, further developments with respect to disputed claims, determinations of the secured status of certain claims, the values of any collateral securing such claims, rejection of executory contracts, continued reconciliation and other events.

While in bankruptcy, the Debtors expect their financial results to continue to be volatile as asset impairments, asset dispositions, contract terminations and rejections and claims assessments may significantly impact the Debtors’ financial statements. As a result, the Debtors’ historical financial performance is likely not indicative of its financial performance after the date of the chapter 11 filings.

Notes to MOR-1a

Copies of Bank Statements and Cash Disbursements Journals. The copies of the Debtors’ bank statements and cash disbursement journals are voluminous and not included herein, but will be provided upon request.

Notes to MOR-4

Copies of IRS Form 6123; Tax Returns. To be provided upon request.

Savient MOR-4. The postpetition accounts payable reported for Debtor Savient Pharmaceuticals, Inc. represent trade vendor invoices that have been entered into the Debtor’s accounts payable system and does not include accruals for invoices not yet received or approved.

 

2


In re: Savient Pharmaceuticals, Inc., et al    Case No. 13-12680 (MFW)
                                                 Debtor    Reporting Period: April 1, 2014 - April 30, 2014
SAVIENT (13-12680): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS   

 

   

BANK ACCOUNT ACTIVITY

FOR THE MONTH ENDED

APRIL 30, 2014

       

CUMULATIVE

FILING TO DATE

OCTOBER 15, 2013

THROUGH

APRIL 30, 2014

 

 
    PNC     AR Lockbox     Fidelity     Wells Fargo     Wells Fargo Utilities    

PNC - LOC (secure

LOC)

   

PNC - LOC (covers

fees)

    Petty Cash         TOTAL         TOTAL  

CASH BEGINNING OF MONTH

  $ 4,321,869      $ 480,747      $ -      $         6,209,254      $ 14,228      $ (0   $ 0      $ 1,000        $ 11,027,098        $ 12,255,382   

RECEIPTS

                       

TRANSFER FROM SUB (SPHI)

    1,000,000        -        -        -        -                        -          1,000,000          14,700,356   

ACCOUNTS RECEIVABLE

    -        183,260        -        -        -                        -          183,260          8,869,088   

TRANSFERS (FROM FIDELITY MM / Lockbox)

    -        -        -        -        -                        -          -          655,368   

STATE MEDICAID REFUNDS

            -        -        -        -                        -          -          98,009   

REFUNDS FROM VENDORS

    44,043        -        -        -        -                        -          44,043          128,224   

ACTAVIS-SALES (oxandrolone royalty)

    -        -        -        -        -                        -          -          125,823   

KINERET CO-PROMOTE REVENUE

    -        -        -        -        -                        -          -          61,859   
TRANSFER FROM OPERATING ACCOUNT (SPHI)     -        -        -        -        -                        -          -          14,228   

COBRA PAYMENTS FROM EMPLOYEES

    -        -        -        -        -                        -          -          35,452   

AMEX RECEIPTS FROM EMPLOYEES

    -        -        -        -        -                        -          -          11,625   

RECEIPTS FROM EMPLOYEE ADVANCES

    -        -        -        -        -                        -          -          1,100   

EQUIPMENT PURCHASES BY EMPLOYEES

    375        -        -        -        -                        -          375          852   

DIVIDENDS ON MONEY MARKET ACCOUNT

    -        -        -        -        -                        -          -          123   

INVESTMENT INCOME FROM CD PORFOLIO

    -        -        -        -        -                        -          -          576   

PROCEEDS FROM SALES TO CREALTA

    -        -        -        -        -                        -          -          116,282,138   

PROCEEDS FROM SALES TO AMNEAL

    -                                                        -          -          76,168   

PNC REFUND PAYMENT TO SAVIENT

    131,371        -        -        -        -                        -          131,371          131,371   
                                                                                  -   

    TOTAL RECEIPTS

  $         1,175,789      $         183,260      $ -      $ -      $ -      $ -      $ -      $ -        $ 1,359,049        $ 141,192,361   

DISBURSEMENTS

                       

PAYMENTS TO NOTE HOLDERS

    17,743        147,000        -        -        -                        -          164,743          126,635,955   

NET PAYROLL

    61,704        -        -        -        -                        -          61,704          3,831,227   

PROFESSIONAL FEES

    4,642,214        -        -        -        -                        -          4,642,214          9,432,150   

CONSULTANT FEES

    22,576                                                                  22,576          67,013   

VENDOR PAYMENTS

    60,694        -        -        -        -                        -          60,694          1,584,297   

EMPLOYEE BENEFITS (401K & Health)

    -        -        -        -        -                        -          -          578,218   

STATE AGENCIES AND TAX PAYMENTS

    9,520        -        -        -        -                        -          9,520          734,556   

TRANSFERS FROM LOCKBOX TO OPERATING ACCOUNT

    -        -        -        -        -                        -          -          655,368   

RENT

    9,667        -        -        -        -                        -          9,667          427,685   

CONCUR (employee expenses)

    -        -        -        -        -                        -          -          270,885   

PAYMENTS TO BOARD OF DIRECTORS

    12,750        -        -        -        -                        -          12,750          220,953   

FUNDING FOR CO-PAY PROGRAM

    -        -        -        -        -                        -          -          36,872   

AMERICAN EXPRESS (employee expenses)

    1,837        -        -        -        -                        -          1,837          34,760   

AMERIFLEX (flex spending)

    149        -        -        -        -                        -          149          32,786   

TRANSFER TO WELLS FARGO UTILITY ACCOUNT

    -        -        -        -        -                        -          -          14,228   

EMPLOYEE EDUCATION REIMBURSEMENT

    -        -        -        -        -                        -          -          12,985   

STORAGE AND WAREHOUSE (INVENTORY)

    -        -        -        -        -                        -          -          4,995   

BANK FEES

    839        -        -        -        -                        -          839          16,529   

SHIPPING AND DELIVERY

    -        -        -        -        -                        -          -          2,265   

PNC SETOFF AGAINST CD

    -        -        -        -        -        -        -        -          -          1,323,191   

PNC REFUND PAYMENT TO SAVIENT

    -        -        -        -        -                -        -          -          131,371   
                                                                                  -   

TOTAL DISBURSEMENTS

  $ 4,839,693      $ 147,000      $ -      $ -      $ -      $ -      $ -      $ -        $ 4,986,693        $ 146,048,289   

    

                       

NET CASH FLOW

  $ (3,663,904   $ 36,260      $ -      $ -      $ -      $ -      $ -      $ -        $ (3,627,644     $ (4,855,928

(RECEIPTS LESS DISBURSEMENTS)

    -        -        -        -        -        -        -        -          -          -   

    

                       

CASH - END OF MONTH

  $ 657,965      $ 517,007      $ -      $ 6,209,254      $ 14,228      $ (0   $ 0      $ 1,000        $ 7,399,454        $ 7,399,454   
* COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE             
                       

DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE

QUARTERLY FEES: (FROM CURRENT MONTH

ACTUAL COLUMN)

   

FOR THE MONTH

ENDED APRIL 30,

2014

   

FOR THE MONTH

ENDED MARCH 31,

2014

   

FOR THE MONTH

ENDED FEBRUARY

28, 2014

   

FOR THE MONTH

ENDED JANUARY

31, 2014

   

FOR THE MONTH

ENDED December

31, 2013

   

FOR THE MONTH

ENDED

NOVEMBER 30,

2013

       

FOR THE PERIOD

OCTOBER 15, 2013

THROUGH
OCTOBER 31, 2013

       

CUMMULATIVE

FILING TO DATE

OCTOBER 15, 2013

THROUGH MARCH

31, 2014

 

TOTAL DISBURSEMENTS

  

  $ 4,986,693      $ 3,043,125      $ 3,227,358      $ 121,139,406      $ 2,492,701      $ 2,396,428          $ 8,762,577          $ 146,048,289   

LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS

  

            403,047        -                -        384,867            13,053            800,967   

LESS: PAYMENT OF U.S. TRUSTEE FEES

  

    30,000                        13,325                                        43,325   

PLUS: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e., from escrow accounts)

  

                    -        -        -        -            -            -   
                        -        -        -        -            -            -   

TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES

  

  $ 4,956,693      $ 2,640,078      $ 3,227,358      $ 121,126,081      $ 2,492,701      $ 2,011,561          $ 8,749,524          $ 145,203,997   


In re: Savient Pharmaceuticals, Inc., et al                                                              

                                         Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SPHI (13-12681): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS

 

    BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
APRIL 30, 2014
    BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
MARCH 31, 2014
    BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
FEBRUARY 28, 2014
        BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
JANUARY 31, 2014
        BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
DECEMBER 31, 2013
        BANK ACCOUNT ACTIVITY
FOR THE MONTH ENDED
NOVEMBER 30, 2013
       

BANK ACCOUNT ACTIVITY
FOR THE PERIOD
OCTOBER 15, 2013

THROUGH

OCTOBER 31, 2013

       

CUMULATIVE
FILING TO DATE
OCTOBER 15, 2013
THROUGH

APRIL 30, 2014

 
    PNC     PNC     PNC         PNC         PNC         PNC         PNC         ACTUAL  

CASH BEGINNING OF MONTH

  $ 3,240,525      $ 3,240,642      $ 3,241,587          $ 3,241,587          $ 3,241,584          $ 3,241,584          $ 16,941,887          $ 16,941,887   
 

RECEIPTS

                         
DIVIDENDS ON MONEY MARKET ACCOUNT     -        -        -            -            3            -            73            76   
      -        -        -            -            -            -            -            -   

TOTAL RECEIPTS

  $ -      $ -      $ -          $ -          $ 3          $ -          $ 73          $ 76   
 

DISBURSEMENTS

                         

TRANSFERS TO SAVIENT OPERATING ACCOUNT

    1,000,000        -        -            -            -            -            13,700,356            14,700,356   

BANK FEES

    -        -        -            -            -            -            20            20   

VENDOR PAYMENTS

    325        118        945            -            -            -            -            1,387   

TOTAL DISBURSEMENTS

  $ 1,000,325      $ 118      $ 945          $ -          $ -          $ -          $ 13,700,376          $ 14,701,763   
                         

NET CASH FLOW

  $ (1,000,325   $ (118   $   (945)        $ -          $ 3          $ -          $ (13,700,303       $ (14,701,687

(RECEIPTS LESS DISBURSEMENTS)

    -        -        -            -            -            -            -            -   
                         

CASH - END OF MONTH

  $ 2,240,200      $ 3,240,525      $ 3,240,642          $ 3,241,587          $ 3,241,587          $ 3,241,584          $ 3,241,584          $ 2,240,200   
                         
                         
 
DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE
QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL
COLUMN)
 

CURRENT MONTH

APRIL 30, 2014

   

CURRENT MONTH

MARCH 31, 2014

   

CURRENT MONTH

FEBRUARY 28, 2014

       

CURRENT MONTH

JANUARY 31, 2014

       

CURRENT MONTH

DECEMBER 31, 2013

       

FOR THE MONTH ENDED

NOVEMBER 30, 2013

        FOR THE PERIOD OCTOBER
15, 2013 THROUGH OCTOBER
31, 2013
        CUMMULATIVE FILING
TO DATE OCTOBER
15, 2013 THROUGH
APRIL 30, 2014
 

TOTAL DISBURSEMENTS

  $ 1,000,325      $ 118      $ 945          $ -          $ -          $ -          $ 13,700,376          $ 14,701,763   

LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS

            -        -            -            -            -            -            -   

LESS: TRANSFERS BETWEEN ACCOUNTS

    1,000,000        -        -            -            -            -            13,700,356            14,700,356   

LESS: PAYMENT OF U.S. TRUSTEE FEES

    325        -        -            -            -            -            -            325   

TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES

  $ -      $ 118      $ 945          $ -          $ -          $ -          $ 20          $ 1,082   


In re: Savient Pharmaceuticals, Inc., et al                                                              

                                             Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SAVIENT (13-12680): BANK RECONCILIATIONS

 

              PNC         PNC Lockbox         Fidelity           Wells Fargo         Wells Fargo Utilities         PNC - Letter of Credit
(secure LOC)
        PNC - Letter Of Credit
(covers fees)
        Petty Cash  
        #              #           #             #              #           #           #           #        

BALANCE PER BOOKS

              $         657,965          $ 517,007          $ -              $     6,209,254          $ 14,228          $ -          $ -          $ 1,000   
                                 

BANK BALANCE

              $ 710,942          $ 517,007          $ -              $ 6,209,254          $ 14,228          $ -          $ -          $ -   

(+) DEPOSITS IN TRANSIT (ATTACH LIST)

                -            -            -                -            -            -            -            -   

(-) OUTSTANDING CHECKS (ATTACH LIST)

                (52,977         -            -                -            -            -            -            -   

OTHER (ATTACH EXPLANATION)

                -            -            -                -            -            -            -            -   

ADJUSTED BANK BALANCE *

              $ 657,965          $ 517,007          $ -              $ 6,209,254          $ 14,228          $ -          $ -          $ -   

* Adjusted bank balance must equal

                                                                                                           

balance per books

                                                                                                           
                                                                                                             

DEPOSITS IN TRANSIT

        Date          Amount      Date       Amount      Date       Amount        Date          Amount      Date       Amount      Date       Amount      Date       Amount      Date       Amount   

NONE

                                                                                                           
                                                                                                             
                                                                                                             

CHECKS OUTSTANDING

        Ck. #          Amount      Ch. #       Amount      Ch. #       Amount        Ck. #          Amount      Ck. #       Amount      Ck. #       Amount      Ck. #       Amount      Ck. #       Amount   
                                                                                                             

Total Outstanding Checks

              $ 52,977                                                                                           
                                                                                                             


In re: Savient Pharmaceuticals, Inc., et al    Case No. 13-12680 (MFW)
                                  Debtor    Reporting Period: April 1, 2014 - April 30, 2014

SPHI (13-12681): BANK RECONCILIATIONS

 

        PNC  
    #        

BALANCE PER BOOKS

        $ 2,240,200   
     

BANK BALANCE

          $ 2,240,200   

(+) DEPOSITS IN TRANSIT (ATTACH LIST)

            -   

(-) OUTSTANDING CHECKS (ATTACH LIST)

            -   

OTHER (ATTACH EXPLANATION)

            -   

ADJUSTED BANK BALANCE *

          $ 2,240,200   

* Adjusted bank balance must equal

               

balance per books

               
                 

DEPOSITS IN TRANSIT

                  Date                                            Amount                  

NONE

               
                 

CHECKS OUTSTANDING

          Ck. #                                  Amount                  

NONE

               
                 


MOR-1a (Addendum)

Savient (13-12680): Open Bank Accounts as of April 30, 2014

 

Account number

  

Bank

  

Type

  

Book Balance

 

 

 

 xxxxxx9201

   Wells Fargo    U.S. Treasury Money Market Fund    $             6,209,254     

 xxxxxx5904

   Wells Fargo    Utilities (Bankruptcy account)    $ 14,228     

 xxxxxx5687

   PNC    Savient Inc Operating Account    $ 657,965     

 xxxxxx1019

   PNC    AR Lockbox    $ 517,007     


MOR-1a (Addendum)

SPHI (13-12681): Open Bank Accounts as of April 30, 2014

 

Account number

  

Bank

  

Type

  

Book Balance

 

 

 

xxxxxx6418

   PNC    SPHI Operating Account    $             2,240,200     


                                                                     In re: Savient Pharmaceuticals, Inc., et al

                                                                                                          Debtor

  

                                                                     Case No. 13-12680 (MFW)

                                                                     Reporting Period: April 1, 2014 - April 30, 2014

                                                                                                                                                                                SAVIENT (13-12680): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

 

Payee

 

Period Covered

 

Amount

Approved

 

Payor

  Check   Amount Paid   Cumulative-To-Date
        Number   Date   Fees   Expenses   Fees   Expenses
                                        
Mary Bordeaux Consulting   10/15-10/31/2013   N/A   Savient Pharmaceuticals, Inc.   67595   11/21/2013   600   -   -   -
Mary Bordeaux Consulting   11/1-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   67651   12/18/2013   1,000   -   -   -
Mary Bordeaux Consulting   12/1-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   67724   1/9/2014   800       -   -
Mary Bordeaux Consulting   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   67796   2/10/2014   1,050   -   3,450   -
The Garden City Group,   Advance   N/A   Savient Pharmaceuticals, Inc.   Wire   11/4/2013   63,400   6,600   -   -
The Garden City Group,   Advance   N/A   Savient Pharmaceuticals, Inc.   Wire   11/5/2013   18,000   7,000   -   -
The Garden City Group,   Advance   N/A   Savient Pharmaceuticals, Inc.   Wire   12/3/2013   80,000   -   -   -
The Garden City Group,   10/15-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   1/3/2014   288,234   57,006   -   -
The Garden City Group,   Advance   N/A   Savient Pharmaceuticals, Inc.   Wire   2/7/2014   6,000   19,000   -    
The Garden City Group,   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   2/13/2014   72,527   42,313   -   -
The Garden City Group,   Advance   N/A   Savient Pharmaceuticals, Inc.   Wire   3/19/2014   64,500   5,500   592,661   137,418
Weiss, Rifkind,   10/14-10/31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   11/19/2013   95,901   1,878   -   -
Weiss, Rifkind,   11/1-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   12/23/2013   189,132   5,669        
Weiss, Rifkind,   12/1-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   1/27/2014   237,592   4,751   -   -
Weiss, Rifkind,   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   2/18/2014   120,274   740   -   -
Weiss, Rifkind,   2/1-28/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   3/31/2014   33,311   514   -   -
Weiss, Rifkind,   3/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   4/29/2014   17,541   184   693,751   13,735
Maples and Calder   11/1-11/29/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   12/18/2013   14,732   -   14,732   -
Shannon, Gracy and Ratlif   10/15-10/26/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   12/18/2013   564   68   -   -
Shannon, Gracy and Ratlif   11/1-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   67736   1/9/2014   1,595   141   -   -
Shannon, Gracy and Ratlif   12/1-25/2013   N/A   Savient Pharmaceuticals, Inc.   67802   2/10/2014   458   3   -   -
Shannon, Gracy and Ratlif   1/1-27/2014   N/A   Savient Pharmaceuticals, Inc.   67869   3/20/2014   170   -   -   -
Shannon, Gracy and Ratlif   2/1-28/2014   N/A   Savient Pharmaceuticals, Inc.   67908   4/10/2014   516   -   3,303   212
The Pine Hill Group   10/15-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   12/13/2013   62,530   -   -   -
The Pine Hill Group   12/1-12/14/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   12/18/2013   15,263   -   -   -
The Pine Hill Group   12/15/2013-1/17/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   1/9/2014   28,788   -   -   -
The Pine Hill Group   1/1-1/17/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   1/21/2014   4,625   -   -   -
The Pine Hill Group   1/20-1/24/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   1/30/2014   5,828   -   -   -
The Pine Hill Group   1/27-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   2/6/2014   5,273   -   -   -
The Pine Hill Group   2/1-14/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   2/18/2014   4,995   -       -
The Pine Hill Group   2/17-28/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   3/4/2014   3,515   -        
The Pine Hill Group   3/1-19/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   3/24/2014   2,590   -   -   -
The Pine Hill Group   3/20-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   4/8/2014   1,110   -   134,516   -
Cole, Schotz, Meisel, Forman & Leonard,  P.A.       10/14-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   1/28/2014   284,120   2,514   -   -
Cole, Schotz, Meisel, Forman & Leonard, P.A.   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   2/13/2014   248,629   1,293   -   -
Cole, Schotz, Meisel, Forman & Leonard, P.A.   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   3/17/2014   268,478   1,374   -   -
Cole, Schotz, Meisel, Forman & Leonard, P.A.   2/1-28/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   4/24/2014   308,439   651   1,109,666   5,832
Deloitte Tax LLP   10/14-11/25/2013   N/A   Savient Pharmaceuticals, Inc.   67710   1/9/2014   7,500   300        
Deloitte Tax LLP   11/25-12/16/2013   N/A   Savient Pharmaceuticals, Inc.   67710   1/9/2014   18,670   747        
Deloitte Tax LLP   11/1-30/2013   N/A   Savient Pharmaceuticals, Inc.   67850   3/6/2014   2,585   103        
Deloitte Tax LLP   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   67850   3/6/2014   37,500   1,500        
Deloitte Tax LLP   3/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   67920   4/30/2014   14,300   572   80,555   3,222
Joele Frank Wilkinson Brimmer   10/11-10/31/2013   N/A   Savient Pharmaceuticals, Inc.   67719   1/9/2014   25,772   6,219        
Joele Frank Wilkinson Brimmer   11/01-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   67719   1/9/2014   5,101   385        
Joele Frank Wilkinson Brimmer   12/01-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   67756   1/17/2014   21,694   9,064   52,567   15,667
Kaufman Dolowich & Voluck, LLP   10/14-10/31/2013   N/A   Savient Pharmaceuticals, Inc.   67720   1/9/2014   2,075            
Kaufman Dolowich & Voluck, LLP   11/01-11/22/2013   N/A   Savient Pharmaceuticals, Inc.   67720   1/9/2014   4,171            
Kaufman Dolowich & Voluck, LLP   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   67865   3/20/2014   63       6,309    
Kramer, Levin, Naftalis & Frankel, LLP   10/14-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   2/7/2014       42,878        
Kramer, Levin, Naftalis & Frankel, LLP   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   2/13/2014   44,591   3,754        
Kramer, Levin, Naftalis & Frankel, LLP   10/14-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   3/4/2014   65,674            
Kramer, Levin, Naftalis & Frankel, LLP   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   4/2/2014   15,105   1,099        
Kramer, Levin, Naftalis & Frankel, LLP   02/1-28/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   4/30/2014   14,011   135   139,382   47,866
Lowenstein Sandler, LLP   10/14-10/31/2013   N/A   Savient Pharmaceuticals, Inc.   67723   1/9/2014   1,851            
Lowenstein Sandler, LLP   11/1-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   67723   1/9/2014   2,897            
Lowenstein Sandler, LLP   12/1-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   67783   1/31/2014   131       -    
Lowenstein Sandler, LLP   01/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   67832   2/27/2014   3,151       -   -
Lowenstein Sandler, LLP   2/1-28/2014   N/A   Savient Pharmaceuticals, Inc.   67876   3/27/2014   316       8,345    
Skadden, Arps, Slate, Meagher & Flom LLP   10/14-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   1/28/2014   1,185,074   19,552   -   -
Skadden, Arps, Slate, Meagher & Flom LLP   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   2/27/2014   788,907   54,617        
Skadden, Arps, Slate, Meagher & Flom LLP   10/14-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   4/24/2014   493,495   -   2,467,477   74,169
Sterne, Kessler, Goldstein, Fox   11/1-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   67738   1/9/2014   1,958       -    
Sterne, Kessler, Goldstein, Fox   12/1-31/2013   N/A   Savient Pharmaceuticals, Inc.   67803   2/10/2014   852   627   2,810   627
Young Conaway Stargatt & Taylor, LLP   10/14-11/30/2013   N/A   Savient Pharmaceuticals, Inc.   Wire   1/14/2014   27,001   616   -   -
Young Conaway Stargatt & Taylor, LLP   12/1-1/31/2014   N/A   Savient Pharmaceuticals, Inc.   Wire   3/6/2014   21,140   64   48,141   680
Lazard Freres & Co., LLC   1/1-31/2014   N/A   Savient Pharmaceuticals, Inc.   WIre   4/2/2014   3,470,634   2,166        
Lazard Freres & Co., LLC   10/14-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   WIre   4/10/2014   240,000   2,255        
Lazard Freres & Co., LLC   10/14-12/31/2013   N/A   Savient Pharmaceuticals, Inc.   WIre   4/24/2014   60,000   -   3,770,634   4,421


  In re: Savient Pharmaceuticals, Inc., et al    Case No. 13-12680 (MFW)
                                  Debtor    Reporting Period: April 1, 2014 - April 30, 2014
                                                       SPHI (13-12681): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

 

Payee

 

Period Covered

 

Amount

Approved

 

Payor

  Check   Amount Paid   Year-To-Date
        Number   Date   Fees   Expenses   Fees   Expenses
No professional fee payments were made by the Debtor during the Reporting Period 4/1/14 through 4/30/14                        
                                        


In re: Savient Pharmaceuticals, Inc., et al

                                     Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

  

SAVIENT (13-12680): STATEMENT OF OPERATIONS

(Income Statement)

 

REVENUES  

For The

                           Month Ended                          

APRIL 30,

2014

   

Cumulative

Filing to Date

                    October 15, 2013                     

Through

April 30, 2014

 

Gross Revenues

  $ -      $ 10,307,196   

Less: Gross-to-Net Adjustments

    -9,428      $ 3,074,563   

Net Revenue

  $ 9,428      $ 7,232,633   

COST OF GOODS SOLD

      -   

Beginning Inventory

  $ -      $ 4,516,751   

Add: Purchases

    -        -   

Add: Cost of Labor

    -        -   

Add: Other Costs (attach schedule)

    -        -   

Less: Ending Inventory

  $ -      $ 3,308,559   

Change in Inventory

    -        1,208,192   

Reclass Sales to Gain/Loss

    -        (1,012,971
              -   

Add: Royalties (MVP & DUKE)

    -        451,915   

Add: Royalties (Office of the Chief Scientist of Israel)

    -        177,122   

Add: Management fee allocation to COGS

    -        93,375   

Add: Stability testing

    -        79,331   

Add: Distribution fees

    -        75,982   

Cost of Goods Sold

  $ -      $ 1,072,946   

Gross Profit

  $ 9,428      $ 6,159,687   

OPERATING EXPENSES

      -   

Research and Development Related Expenses:

            -   

Investigator grants

  $ -      $ 150,000   

QC & Stability testing

    -        60,360   

CRO costs

    -        111,312   

Pharmacovigilance

    -        54,744   

Process development and Improvement

    -        23,878   

IP Related

    0        12,836   

Central labs

    0        8,958   

REMS Communication and assessment

    -        7,590   

Publications

    0        6,891   

Research

    0        1,407   

Medical education

    0        -   

Total Research and Development Related Expenses

  $ -      $ 437,976   
            $ -   

Selling and Marketing Related Expenses:

            -   

Pricing and reimbursement

  $ -      $ 171,166   

Exhibit booth

    -        69,019   

Speakers programs

    -        52,882   

Maketing and other promotional activity

    -        61,261   

Medical meetings and symposia

    -        38,167   

Medical education

    -        26,193   

Market research

    -        5,585   

Publications

    -        78   

Total Selling and Marketing Related Expenses

  $ -      $ 424,351   
            $ -   

General and Administrative Related Expenses:

            -   

Compensation and related benefits and taxes

  $ 54,631      $ 3,992,261   

Insurance (amortization of prepaid insurance)

    85,879        1,225,786   

Share-based compensation (SFAS 123-R expense)

    -        696,522   

Sales force commissions

    -        351,582   

Occupancy

    9,667        454,084   

Travel and entertainment

    313        235,954   

Accrued Board of Directors’ cash payments & meeting fees

    18,417        219,288   

Outside consulting services

    -        137,126   

Corporate communications and investor relations

    2,122        122,990   

Legal

    -        132,948   

Licenses and information

    -        62,133   

Communications (Utilities)

    4,127        52,677   

General expenses and office supplies

    32,563        177,072   

Postage and Shipping

    446        7,534   

Total General and Administrative Related Expenses:

  $ 208,165      $ 7,867,957   

Total Operating Expenses Before Depreciation

  $ 208,165      $ 8,730,284   

Depreciation and amortization

    -        110,582   

Net Loss Before Other Income & Expenses

  $ (198,737   $ (2,681,179
      -   

OTHER INCOME AND (EXPENSES)

      -   

Dividend/Interest income

  $ -      $ 757   

Interest Expense on capital leases

    -        (2,488

Other Income

    28,386        28,386   

Bank charges

    (839     (16,609

Net Profit (Loss) Before Reorganization Items

  $ (171,190   $ (2,671,133

REORGANIZATION ITEMS

      -   

Proceed from Sale to Crealta

  $ -      $ (116,282,138

Distribution to Noteholders

  $ 164,743      $ 126,635,955   

Professional Fees

    571,475        12,895,833   

Cure Cost

    -        (2,393,690

Accrual Adjustments (Changes in estimates)

    -        (901,303

U. S. Trustee Quarterly Fees

    30,000        43,325   

Interest Earned on Accumulated Cash from Chapter 11 (see continuat

    -        -   

Gain (Loss) from Sale of Equipment

    -        (3,123,031

Impairment of Assets

            1,569,540   

Impairment write-down of LOC security deposit

    -        1,323,249   

Transfer from SPHI

    (1,000,000     (1,000,000

Total Reorganization Expenses

  $ (233,783   $ 18,767,740   

Income Taxes

            -   

Net Profit (Loss)

  $ 62,592      $ (21,438,873
   
*“Insider” is defined in 11 U.S.C. Section 101(31).    


In re: Savient Pharmaceuticals, Inc., et al

                                         Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SPHI (13-12681): STATEMENT OF OPERATIONS

(Income Statement)

 

REVENUES   

For The

            Month Ended             

April 30,

2014

   

Cumulative

Filing to Date

        October 15, 2013        

Through

April 30, 2014

 

NOT APPLICABLE

   $ -      $ -   
             $ -   

COST OF GOODS SOLD

             -   

NOT APPLICABLE

   $ -      $ -   
             $ -   

OPERATING EXPENSES (NONE NOTED FOR THE CURRENT PERIOD)

             -   
             $ -   

General and Administrative Related Expenses:

             -   

Compensation and related benefits and taxes

   $ -      $ -   

Share-based compensation

     -        -   

Accrued sales commissions (SFAS 123-R expense)

     -        -   

Insurance (Amortization of prepaid insurance)

     -        -   

Travel and entertainment

     -        -   

Occupancy

     -        -   

Outside consulting services

     -        -   

General expenses and office supplies

     -        1,063   

Accrued Board of Directors’ cash payments

     -        -   

Communications (Utilities)

     -        -   

Legal expenses

     -        -   

Corporate communications and investor relations

     -        -   

Total General and Administrative Related Expenses:

   $ -      $ 1,063   

Total Operating Expenses Before Depreciation

   $ -      $ 1,063   

Depreciation and amortization

     -        -   

Net Loss Before Other Income & Expenses

   $ -      $ (1,063
       -   

OTHER INCOME AND (EXPENSES)

             -   

Dividend income

   $ -      $ 76   

Interest Expense on capital leases

     -        -   

Bank charges

     -        (20

Net Profit (Loss) Before Reorganization Items

   $ -      $ (1,007

REORGANIZATION ITEMS

             -   

Impairment of intercompany note receivable from Parent (Savient)

   $ -      $ 13,700,356   

Transfer of Funds to Savient

   $ 1,000,000      $ 1,000,000   

Trustee Fees

   $ 325      $ 325   
       -        -   

Total Reorganization Expenses

   $ 1,000,325      $ 14,700,681   

Income Taxes

     -        -   

Net Profit (Loss)

   $ (1,000,325   $ (14,701,688

*“Insider” is defined in 11 U.S.C. Section 101(31).

    


In re: Savient Pharmaceuticals, Inc., et al

                                                                              Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SAVIENT (13-12680): BALANCE SHEET

 

ASSETS   

            BOOK VALUE AT             

APRIL 30, 2014    

    

            BOOK VALUE ON             

PETITION DATE

 
CURRENT ASSETS              

Cash and cash equivalents

                 

Petty cash

   $ 1,000       $ 1,000   

PNC Bank business operating account

     657,964         4,207,573   

PNC AR Lockbox

     517,007            

Wells Fargo utilities account

     14,228         -   

Fidelity U.S. Treasury money market account

     -         383,689   

Wells Fargo money market account

     6,209,254         3,169,442   

PNC Letter of Credit (Acct # 31900362019 - Secure the LOC)

     -         1,304,340   

PNC Letter of Credit (Acct #31800362548 - Covers LOC Fees)

     -         150,222   

Total cash and cash equivalents

   $ 7,399,453       $ 9,216,266   

    

                 

Short-term investments

                 

Wells Fargo CD Portfolio

   $ -       $ 3,039,116   

Total short-term investments

   $ -       $ 3,039,116   
                -   

Accounts receivable (Net)

   $ 4,229,677       $ 7,088,730   

Inventories (Net)

   $ -       $ 1,208,192   

    

                 

Prepaid expenses and other current assets

                 

Prepaid D&O insurance

   $ 1,914,960       $ 2,603,465   

Professional retainers

     933,427         1,552,562   

Other receivables non-trade

     291,208         622,746   

Prepaid-other

     64,129         313,115   

Prepaid-other insurance

     69,835         221,089   

Prepaid rent

     9,667         65,698   

Prepaid marketing costs (YNF- Co-pay program)

     -         83,424   

Prepaid product liability insurance

     -         96,338   

Advances to employees

     -         600   

Total prepaid expenses and other current assets

   $ 3,283,226       $ 5,559,037   

    

                 

TOTAL CURRENT ASSETS

   $ 14,912,356       $ 26,111,341   

PROPERTY AND EQUIPMENT

     

Office equipment

   $ -       $ 656,229   

Other furniture and fixtures

     -         6,005   

Leasehold Improvements

     -         1,496,216   

Capital lease assets

     -         212,770   

Less Accumulated Depreciation

     -         (684,933

TOTAL PROPERTY & EQUIPMENT

   $ -       $ 1,686,287   

OTHER ASSETS

     

Investment in wholly-owned subsidiary (Savient Pharma Holdings, SPHI)

   $ 147,259,564       $ 147,259,564   

Investment in wholly-owned subsidiary (Savient Pharma Ireland, Limited, SPIL)

     134         134   

TOTAL OTHER ASSETS

   $ 147,259,698       $ 147,259,698   
     

TOTAL ASSETS

   $ 162,172,054       $ 175,057,326   


LIABILITIES AND OWNER EQUITY   

            BOOK VALUE AT             

APRIL 30, 2014    

   

            BOOK VALUE ON             

PETITION DATE

 
LIABILITIES NOT SUBJECT TO COMPROMISE (Postpetition)             

Accounts payable

   $ 11,357      $ 12,972   

Accrued expenses

                

Accrued professional fees

   $ 3,017,155      $ -   

Accrued employee expense reimbursement

     -        13,093   

Other accrued postpetition liabilities

     88,162        -   

Total accrued expenses

   $ 3,105,317      $ 13,093   

    

                

Other liabilities not subject to compromise

                

Accrued royalties payable

   $ -      $ 943,189   

Deferred revenue

     -        936,535   

Reserve for returns

     -        407,355   

Reserve for chargeback’s

     6,175        264,528   

Reserve for Medicaid claims

     39,994        241,584   

Capital lease liability

     -        185,672   

Accrued distribution fees

     13,632        44,528   

Accrued Delaware franchise taxes

     38,920        58,380   

Accrued sales and use taxes

     3,424        -   

Accrued payroll taxes (Puerto Rico)

     -        -   

Total other liabilities not subject to compromise

   $ 102,145      $ 3,081,771   

    

                

TOTAL LIABILITIES NOT SUBJECT TO COMPRMISE (POSTPETITION LIABILITIES)

   $ 3,218,819      $ 3,107,836   

LIABILITIES SUBJECT TO COMPROMISE (Pre-Petition)

    

Accounts payable

   $ 849,096      $ 1,402,335   

Accrued expenses

                

Other accrued pre-petition liabilities

   $ 1,239,587      $ 1,818,953   

Total accrued expenses

   $ 1,239,587      $ 1,818,953   

    

                

Other liabilities subject to compromise

                

Senior Secured 2019 Notes

   $ 144,257,695      $ 144,257,695   

Subordinated Debt 2018 Convertible Notes

     99,555,240        99,555,240   

Intercompany loan payable to wholly owned subsidiary Savient Pharma Holdings, SPHI

     29,204,944        15,504,588   

Accrued Purchase commitment reserve

     -        3,771,066   

Accrued Severance liability

     2,102,695        2,102,695   

Warrant Liability

     1,479,776        1,479,776   

Accrued home office bonuses

     1,370,749        1,370,749   

Accrued Sales commissions

     733,400        820,357   

Embedded conversion features liability 2018 convertible notes

     848,100        848,100   

Accrued retention bonuses

     821,030        821,030   

Accrued vacation

     -        281,395   

Employee benefit related (flex spending liabilities)

     -        50,597   

Total other liabilities subject to compromise

   $ 280,373,629      $ 270,863,288   

    

                

TOTAL LIABILITIES SUBJECT TO COMPRIMISE (PRE-PETITION)

   $ 282,462,312      $ 274,084,576   

    

                

TOTAL LIABILITIES

   $ 285,681,131      $ 277,192,412   

OWNER EQUITY

    

Common Stock

   $ 736,949      $ 736,949   

Additional Paid-In Capital

     401,447,969        400,739,096   

Retained Earnings - Pre-Petition

     (504,255,122     (503,611,131

Retained Earnings - Postpetition

     (21,438,873        

NET OWNER EQUITY

   $ (123,509,077   $ (102,135,086
     

TOTAL LIABILITIES AND OWNERS’ EQUITY

   $ 162,172,054      $ 175,057,326   


In re: Savient Pharmaceuticals, Inc., et al

                                                                          Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SPHI (13-12681): BALANCE SHEET

 

ASSETS   

        BOOK VALUE AT        

APRIL 30, 2014    

   

        BOOK VALUE ON        

PETITION DATE

 
CURRENT ASSETS             

Cash and cash equivalents

                

PNC Bank business operating account

     2,240,200        3,241,604   

Fidelity U.S. Treasury money market account

     -        13,700,283   

Total cash and cash equivalents

   $ 2,240,200      $ 16,941,887   

    

                

TOTAL CURRENT ASSETS

   $ 2,240,200      $ 16,941,887   
     

TOTAL ASSETS

   $ 2,240,200      $ 16,941,887   

    

    

OWNER EQUITY

    

Common Stock

   $ 1      $ 1   

Additional Paid-In Capital

     147,259,563        147,259,563   

Retained Earnings - Pre-Petition

     (130,317,677     (130,317,677

Retained Earnings - Postpetition

     (14,701,687     -   

NET OWNER EQUITY

   $ 2,240,200      $ 16,941,887   
     

TOTAL LIABILITIES AND OWNERS’ EQUITY

   $ 2,240,200      $ 16,941,887   


In re: Savient Pharmaceuticals, Inc., et al    Case No. 13-12680 (MFW)
                                Debtor    Reporting Period: April 1, 2014 - April 30, 2014

SAVIENT (13-12680): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of April 30, 2014 and paid in the ordinary course by the Debtor.

SUMMARY OF UNPAID POSTPETITION DEBTS

 

                                                                                               
    Number of Days Past Due  
    Current     0-30     31-60     61-90     Over 90     Total  

Accounts Payable

  $ 11,357      $ -      $ -      $ -      $ -      $ 11,357   

Employee Expenses Payable (Concur)

    -        -        -        -        -      $ -   

Wages Payable

    -        -        -        -        -        -   

Taxes Payable

    -        -        -        -        -        -   

Rent/Leases-Building

    -        -        -        -        -        -   

Rent/Leases-Equipment

    -        -        -        -        -        -   

Secured Debt/Adequate Protection Payments

    -        -        -        -        -        -   

Professional Fees

    -        -        -        -        -        -   

Amounts Due to Insiders

    -        -        -        -        -        -   

Total Postpetition Debts

  $ 11,357      $ -      $ -      $ -      $ -      $ 11,357   


In re: Savient Pharmaceuticals, Inc., et al

                                     Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SPHI (13-12681): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of April 30, 2014 and paid in the ordinary course by the Debtor.

SUMMARY OF UNPAID POSTPETITION DEBTS

The Debtor is current on all postpetition debts.


In re: Savient Pharmaceuticals, Inc., et al                                                                  

                                   Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SAVIENT (13-12680): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

 

Accounts Receivable Reconciliation      

BOOK VALUE AT

APRIL 30, 2014

   

BOOK VALUE AT

MARCH 31, 2014

   

BOOK VALUE AT

FEBRUARY 28, 2014

   

BOOK VALUE AT

JANUARY 31, 2014

   

BOOK VALUE AT

DECEMBER 31, 2013

   

BOOK VALUE AT

NOVEMBER 30, 2013

   

BOOK VALUE AT

OCTOBER 31, 2013

 

Total Accounts Receivable at the beginning of the reporting period

      $ 4,441,105      $ 4,884,101      $ 5,936,972      $ 7,434,952      $ 7,372,339      $ 7,116,283        7,045,577   

+ Amounts billed during the period

        -        -        -        1,162,843        3,365,207        2,570,042        2,177,755   

- Amounts collected during the period

        (183,260     (439,034     (1,030,335     (2,168,659     (2,294,795     (1,243,215     (1,455,908

- Discounts and Chargeback’s

        (25,150     (4,608     (7,748     (457,211     (953,422     (1,036,869     (600,708

- Return Credits

        -        -        -        (5,037     (19,364     (2,551     (20,378

- Prompt Pay Discounts

        (3,018     647        (14,788     (29,916     (35,013     (31,351     (30,055

Total Accounts Receivable at the end of the reporting period

      $ 4,229,676      $ 4,441,105      $ 4,884,101      $ 5,936,972      $ 7,434,952      $ 7,372,339      $ 7,116,283   

- Provision for discounts

        -        -        -        -        (49,626     (34,907     (59,679

+ Accounts receivable other

        -        -        -        73,838        67,200        47,612        22,795   

Total Accounts Receivable, Net at the end of the reporting period

      $ 4,229,676      $ 4,441,105      $ 4,884,101      $ 6,010,810      $ 7,452,526      $ 7,385,044      $ 7,079,399   
                                               
Accounts Receivable Aging       BOOK VALUE AT
APRIL 30, 2014
    BOOK VALUE AT
MARCH 31, 2014
    BOOK VALUE AT
FEBRUARY 28, 2014
    BOOK VALUE AT
JANUARY 31, 2014
    BOOK VALUE AT
DECEMBER 31, 2013
    BOOK VALUE AT
NOVEMBER 30, 2013
    BOOK VALUE AT
OCTOBER 31, 2013
 

0 - 30 days old

      $ (12,726   $ 155,101      $ 995,123      $ 2,815,441      $ 4,635,949      $ 5,679,858        5,672,068   

31 - 60 days old

        (1,991     385,183        781,474        315,136        1,177,031        263,279        -   

61 - 90 days old

        352,843        799,201        420,865        1,125,299        187,404        6,427        21,440   

91+ days old

        3,891,551        3,101,621        2,686,639        1,681,095        1,434,568        1,422,775        1,422,775   

Total Accounts Receivable at the end of the reporting period

      $ 4,229,677      $ 4,441,105      $ 4,884,101      $ 5,936,972      $ 7,434,952      $ 7,372,339      $ 7,116,283   

- Provision for discounts

        -        -        -        -        (49,626     (34,907     (59,679

+ Accounts receivable other

        -        -        -        73,838        67,200        47,612        22,795   

Total Accounts Receivable, Net at the end of the reporting period

      $ 4,229,677      $ 4,441,105      $ 4,884,101      $ 6,010,810      $ 7,452,526      $ 7,385,044      $ 7,079,399   

DEBTOR QUESTIONNAIRE

  

Must be completed each month       Yes     No                                

1.

  Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.     X*                     

2.

  Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.             X             

3.

  Have all postpetition tax returns been timely filed? If no, provide an explanation below.     X                     

4.

  Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.     X                     

5.

  Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.             X             

* Debtor sold de minimis assets in the amount of $375 during the month of April.


In re: Savient Pharmaceuticals, Inc., et al

                                     Debtor

  

Case No. 13-12680 (MFW)

Reporting Period: April 1, 2014 - April 30, 2014

SPHI(13-12681): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING

 

Accounts Receivable Reconciliation           Amount    

NOT APPLICABLE

          $                                 -    
         
Accounts Receivable Aging           Amount    

NOT APPLICABLE

          $                                 -    
         
DEBTOR QUESTIONNAIRE
Must be completed each month                       Yes                                        No                    

1.   Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.

      X

2.   Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.

      X

3.   Have all postpetition tax returns been timely filed? If no, provide an explanation below.

  X    

4.   Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.

  X    

5.   Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.

      X